Lumida
/IBRX
⌘K
Immunitybio Inc

Immunitybio Inc

IBRX
$7.91USD+2.46%+0.19 today

MARKET CAP

8.4B

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $8

52W RANGE

$2
$12

AI Summary

Stalk
StalkMedium

IBRX remains in a Stage 2 consolidation above its rising 200DMA after the mid-Feb parabolic spike and collapse. Short-term EMAs (9/20/50) are flat and price sits slightly below the cluster, with neutral RSI and Options Score signaling no clear timing edge. Medium-term bias stays bullish in this range-bound structure, but execution should await support near the lower range or a decisive reclaim of the EMA cluster.

  • Q2 2026 net revenues $50.7 M, up 92% YoY.
  • ANKTIVA revenues projected to hit $210 M (+85% YoY) in 2026.
  • Negative profitability factors suggest unsustainable margin structure.
Full analysis →
Insider Trades22 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Feb 22, 2026SellIBRXRegan J LauerChief Accounting Officer1,673$8.70$8.4B-36.36%+305.64%$14.6K-1.38%Trim
Feb 22, 2026SellIBRXDavid C. SachsChief Financial Officer20,682$8.70$8.4B-36.36%+305.64%$179.9K-5.72%Trim
Feb 22, 2026SellIBRXPatrick Soon-Shiong58,170$8.70$8.4B-36.36%+305.64%$506.1K-0.19%Trim
Feb 22, 2026SellIBRXRichard AdcockCEO & President77,560$8.70$8.4B-36.36%+305.64%$674.8K-9.81%Trim
Feb 10, 2026SellIBRXRegan J LauerChief Accounting Officer2,257$6.93$8.4B-36.36%+305.64%$15.6K-1.78%Trim
Feb 10, 2026SellIBRXDavid C. SachsChief Financial Officer42,643$6.93$8.4B-36.36%+305.64%$295.5K-8.75%Trim
Feb 10, 2026SellIBRXPatrick Soon-Shiong118,560$6.93$8.4B-36.36%+305.64%$821.6K-0.39%Trim
Feb 10, 2026SellIBRXRichard AdcockCEO & President140,048$6.93$8.4B-36.36%+305.64%$970.5K-11.93%Trim
Dec 31, 2025SellIBRXDavid C. SachsChief Financial Officer15,435$1.98$8.4B-36.36%+305.64%$30.6K-5.12%Trim
Dec 31, 2025SellIBRXRichard AdcockCEO & President17,510$1.98$8.4B-36.36%+305.64%$34.7K-4.16%Trim
Feb 22, 2025SellIBRXRegan J LauerChief Accounting Officer1,669$3.42$8.4B-36.36%+305.64%$5.7K-1.39%Trim
Feb 22, 2025SellIBRXDavid C. SachsChief Financial Officer15,860$3.42$8.4B-36.36%+305.64%$54.2K-4.91%Trim
Feb 22, 2025SellIBRXPatrick Soon-Shiong42,071$3.42$8.4B-36.36%+305.64%$143.9K-0.14%Trim
Feb 22, 2025SellIBRXRichard AdcockCEO & President78,167$3.42$8.4B-36.36%+305.64%$267.3K-10.89%Trim
Dec 31, 2024SellIBRXDavid C. SachsChief Financial Officer15,405$2.56$8.4B-36.36%+305.64%$39.4K-5.27%Trim
Dec 31, 2024SellIBRXRichard AdcockCEO & President17,475$2.56$8.4B-36.36%+305.64%$44.7K-4.80%Trim
Dec 15, 2024SellIBRXRegan J LauerChief Accounting Officer7,503$2.87$8.4B-36.36%+305.64%$21.5K-6.50%Trim
Feb 5, 2024SellIBRXRichard AdcockCEO & President43,165$4.04$8.4B-36.36%+305.64%$174.4K-15.08%Trim
Jan 31, 2024SellIBRXRegan J LauerChief Accounting Officer13,470$3.36$8.4B-36.36%+305.64%$45.3K-12.49%Trim
Jan 31, 2024SellIBRXDavid C. SachsChief Financial Officer26,835$3.36$8.4B-36.36%+305.64%$90.2K-12.62%Trim
Dec 31, 2023SellIBRXDavid C. SachsChief Financial Officer10,511$5.02$8.4B-36.36%+305.64%$52.8K-4.06%Trim
Dec 31, 2023SellIBRXRichard AdcockCEO & President17,096$5.02$8.4B-36.36%+305.64%$85.8K-5.02%Trim